Table 5 Association between PET parameters and progression free survival, for ipilimumab and anti-PD1 treatment, analysed as continuous variable and dichotomized at the median for the cohort

PET

parameter

Level

n

HR

HR 95% CI

P-value

Level

n

HR

HR 95% CI

P-value

Tumoral SUVmax

0.997

[0.978, 1.02]

0.74

0.984

[0.958, 1.01]

0.23

MTV (mL)

1.07

[1.01, 1.14]

0.066

0.993

[0.924, 1.07]

0.86

SLR

8.24

[1.08, 63.1]

0.05

0.904

[0.0623, 13.1]

0.94

Tumoral SUVmax

≤18

39

1

–

0.348

≤18

16

1

–

0.56

> 18

31

0.78

[0.46, 1.31]

> 18

24

0.81

[0.39, 1.66]

MTV (mL)

≤41

34

1

–

0.231

≤140

20

1

–

0.86

> 41

36

1.45

[0.79, 2.68]

> 140

20

0.94

[0.46, 1.90]

SLR

≤1.1

60

1

–

0.008

≤1.1

35

1

–

0.32

> 1.1

9

3.14

[1.46, 6.75]

> 1.1

5

0.56

[0.16, 1.92]